Examining the Legislative Landscape for Rare Disease Drug Development

Amanda Malakoff, executive director of the Rare Disease Company Coalition, discusses the policy landscape for rare disease therapies, unfinished business from the recent passage of a lean Prescription Drug User Fee Act, and policy priorities for 2023.